Will Sanofi Overpay For Actelion Innovation Or, Like J&J, Also Walk Away?
Executive Summary
Reported M&A talks between Sanofi and Actelion will likely stand or fall on the former's willingness to overpay and the target's demanded price for surrendering its independence.
You may also be interested in...
J&J’s $30bn For Actelion Buys Immediate And Longer-Term Value
In this tale of two companies, it's the best of times and the best of times. J&J gets immediate value by acquiring Actelion's blockbuster PAH franchise and its late-stage pipeline, while its stake in an Actelion spinout offers longer-term potential.
J&J's Actelion Courtship Seen Unaffected By Macitentan MAESTRO Failure
Johnson & Johnson is expected to keep pursuing Actelion despite news the target's pulmonary arterial hypertension drug macitentan missed a primary endpoint in a Phase III study of patients with PAH due to Eisenmenger Syndrome.
Was Sanofi’s Offer One That Actelion Could Refuse? J&J Back At Bargaining Table
Johnson & Johnson is back at the M&A bargaining table with Actelion after walking away from negotiations a week ago, raising questions about whether Sanofi’s deal terms were harder to digest than J&J’s.